Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.88 |
| ▸ | BTK | Q06187 | 12/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29841448 | 1.00 | EGFR (0.88) | EGFRBTK | |
| SCHEMBL31070350 | 0.96 | EGFR (0.81) | EGFRBTK | |
| SCHEMBL29841271 | 0.96 | EGFR (0.83) | EGFRBTK | |
| SCHEMBL24734999 | 0.96 | EGFR (0.83) | EGFRBTK | |
| SCHEMBL24734993 | 0.96 | EGFR (0.83) | EGFRBTK | |
| SCHEMBL24735215 | 0.93 | EGFR (0.86) | EGFRBTK | |
| SCHEMBL18665608 | 0.93 | EGFR (1.00) | EGFRBTK | |
| SCHEMBL29841335 | 0.93 | EGFR (0.86) | EGFRBTK | |
| SCHEMBL31188072 | 0.92 | EGFR (0.86) | EGFRBTK | |
| SCHEMBL31188064 | 0.92 | EGFR (0.86) | EGFRBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117042769-A | Substituted pyrrolopyrimidines and pyrazolopyrimidines as Bruton's Tyrosine Kinase (BTK) degrading agents | 冰洲石生物科技公司 | 2023-11-10 | — | — | CN | disclosed |
| US-11530222-B2 | Substituted pyrrolopyrimidine and pyrazolopyrimidine as Bruton's tyrosine kinase (BTK) degraders | ACCUTAR BIOTECHNOLOGY INC. (US) | 2022-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530222-B2 | Substituted pyrrolopyrimidine and pyrazolopyrimidine as Bruton's tyrosine kinase (BTK) degraders | BTK, LYN, SYK | EGFR 804/4885BTK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.